TPP collaborates with University of Edinburgh
Will focus on commercialisation opportunities in CNS, immunology and inflammation and oncology
UK drug developer TPP Global Development (TPP) is to collaborate with the University of Edinburgh on the development of novel pre-clinical intellectual property originated within the University.
The organisations will focus on commercialisation opportunities in the areas of nervous system disorders, immunology/inflammation and oncology. Initially the agreement will run for five years, after which it may be extended.
Thomas Brown, TPP’s ceo, said: ‘We are delighted to have entered into this agreement with the University of Edinburgh. They rank amongst the global elite in terms of academic excellence and ability to originate novel IP.’
Professor Jonathan Seckl, director of research for the College of Medicine and Veterinary Medicine at the University of Edinburgh, added: ‘I am delighted that TPP has recognised the enormous commercial potential encompassed within Edinburgh's globally-leading basic and translational medical and veterinary research. We look forward to some successful interactions with TPP in the years to come.’